Entyvio is a prescription medication that reduces inflammation in the digestive tract by blocking immune cells from entering gut tissue. It treats moderate to severe inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis.
Entyvio (vedolizumab) is a monoclonal antibody designed to target and bind to a protein called α4β7 integrin. This protein helps immune cells move from the bloodstream into gut tissue. By blocking α4β7 integrin, Entyvio prevents immune cells from causing inflammation in the gut. Unlike other IBD treatments, Entyvio specifically targets the gut, minimizing effects on the rest of the immune system.
Entyvio is approved for two primary types of IBD:
Some patients confuse Entyvio with other biologics like Humira or Remicade, which target different pathways in the immune system. Unlike those medications, Entyvio does not affect the entire immune system but focuses solely on gut inflammation. This targeted approach may reduce the risk of infections compared to broader immune-suppressing drugs.
Entyvio is administered intravenously (IV) in a clinical setting. The typical dosing schedule includes an initial dose, followed by additional doses at specific intervals. For example, the standard regimen is a 300 mg infusion at weeks 0, 2, and 6, then every eight weeks thereafter. The medication is usually well-tolerated, with common side effects including headache, nasopharyngitis, and arthralgia.
I've seen firsthand how Entyvio can improve a patient's quality of life. One patient I worked with experienced significant relief from frequent flare-ups after starting Entyvio, allowing them to return to daily activities without constant discomfort.
Doctors often recommend Entyvio for patients who have not responded well to other treatments like corticosteroids, immunosuppressants, or different biologics. It is particularly useful for those seeking a treatment with a lower risk of systemic infections due to its gut-specific mechanism.